Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics

BMJ Case Rep. 2019 Sep 4;12(9):e230193. doi: 10.1136/bcr-2019-230193.

Abstract

A 76-year-old man presented with complaints of increased confusion, visual hallucinations and decline in memory. He was admitted to the hospital and started on quetiapine 50 mg daily for symptom management. Shortly after, he was diagnosed with Lewy body dementia and started on rivastigmine, a cholinesterase inhibitor (ChEI), at 1.5 mg two times per day. The patient's symptoms continued to worsen and antipsychotics increased for aggressive behaviour. After he became physically aggressive, an extensive medication management review was conducted, prompting an alternative treatment strategy. The quetiapine dose was reduced from 150 mg daily to 12.5 mg daily, his rivastigmine was increased to 3 mg two times per day and all other antipsychotics were discontinued. The up-titration of his rivastigmine after 10 days of therapy was well tolerated with no adverse effects. He demonstrated a clear clinical response to optimised ChEI therapy and low dose quetiapine, showing improvements in alertness and functioning.

Keywords: memory disorders; psychiatry (drugs and medicines); psychotherapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects*
  • Cholinesterase Inhibitors / administration & dosage*
  • Dose-Response Relationship, Drug
  • Hallucinations / etiology
  • Humans
  • Lewy Body Disease / complications
  • Lewy Body Disease / diagnosis
  • Lewy Body Disease / drug therapy*
  • Male
  • Psychotic Disorders / etiology
  • Quetiapine Fumarate / administration & dosage
  • Quetiapine Fumarate / adverse effects*
  • Rivastigmine / administration & dosage*

Substances

  • Antipsychotic Agents
  • Cholinesterase Inhibitors
  • Quetiapine Fumarate
  • Rivastigmine